Skip to content
Back to all posts

Which Biologic & When

- In: Clinical Practice, Pharma

Psoriasis: Which Biologic & When by Craig Teller MD

  • Certolizumab pegol demonstrated minimal transfer in the second and third trimester of pregnancy and found in very low or undetectable levels in breastmilk.
  • TNFs and ustekinumab can be used to treat psoriasis in HIV. Secukinumab has been demonstrated to be safe in patients with previous Hep B infection and active Hep B infection. IL-17s can be used in patients with latent TB.
  • PsA arises due to an interaction between genetic and environmental factors that trigger release of proinflammatory cytokines at multiple sites. Microbial dysbiosis may initiate inflammation in the ileocolon and trigger IL-23 and Th17 cells.